Content area

|
|

Metformin er en mulig glukagonlignende peptid-1-stimulator

Forfatter(e)

Emilie Bahne1, Andreas Brønden1, Tina Vilsbøll1, 2, 3 & Filip Krag Knop1, 3, 4

1) Center for Diabetesforskning, Gentofte Hospital 2) Steno Diabetes Center Copenhagen, Gentofte 3) Institut for Klinisk Medicin, Det Sundhedsvidenskabelige Fakultet, Københavns Universitet 4) The Novo Nordisk Foundation Center for Basic Metabolic Research, Det Sundhedsvidenskabelige Fakultet, Københavns Universitet Ugeskr Læger 2018;180:V07170516

Reference: 
Ugeskr Læger 2018;180:V07170516
Blad nummer: 
Sidetal: 
2-5
Metformin is a possible glucagon-like peptide 1 stimulator

Metformin is an oral anti-hyperglycaemic drug used as first-line treatment of Type 2 diabetes. It is more effective when administered orally than when administered intravenously, and metformin formulations, which prolong the time residing in the gut are the most potent. This indicates that the intestine plays an essential role in metformin’s mode of action. Metformin also increases plasma concentrations of the glucose-lowering gut incretin hormone glucagon-like peptide-1 (GLP-1). This metformin-induced GLP-1 increment may constitute an important link between the gut and the glucose-lowering effect of metformin.

Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Anna Birthe Holmehøj Bach | 04/12
1 Kommentar
af Susanne L. M. Bülow | 03/12
1 Kommentar
af Andreas Gothardt Lundh | 02/12
1 Kommentar
af Michael Uldall Steinfath | 01/12
1 Kommentar
af Pedram Kazemi-Esfarjani | 01/12
1 Kommentar
af Bjarne Stigsby | 30/11
2 kommentarer
af Camilla Bang | 29/11
2 kommentarer
af Stine Madsen-Østerbye | 29/11
1 Kommentar